OPKO HEALTH Business Summary

OPKO Health, Inc. (OPK) operates as a diversified healthcare company utilizing a multi-pillar revenue model centered on diagnostic services, pharmaceutical product sales, and high-value licensing royalties. The company’s Laboratory Services segment, led by BioReference Health, generates revenue through clinical testing services, though it recently underwent a strategic contraction following the 2025 sale of its oncology assets to Labcorp to focus on core clinical and correctional health markets. Its Pharmaceutical segment drives growth through the commercialization of Rayaldee and global profit-sharing from NGENLA, a once-weekly growth hormone developed with Pfizer. Additionally, OPKO leverages its ModeX Therapeutics subsidiary to secure non-dilutive funding via massive R&D collaborations, such as its 2026 multispecific antibody deal with Regeneron valued at over $1 billion. Within the market, OPKO competes with specialized diagnostic firms like Castle Biosciences and Fulgent Genetics, as well as biotech peers such as Ligand Pharmaceuticals and BioCryst Pharmaceuticals, positioning itself as a hybrid entity transitioning from a legacy lab provider to a high-margin therapeutics innovator. Leadership is anchored by a founding trio that consolidated the firm in 2007: Chairman and CEO Phillip Frost, M.D., Vice Chairman and CTO Jane Hsiao, Ph.D., and EVP Steven Rubin. Dr. Frost, a billionaire physician-investor, previously served as Chairman of Teva Pharmaceutical Industries and CEO of IVAX Corporation, while Dr. Hsiao brings extensive technical pedigree from IVAX and various biotech boards. The executive team is further bolstered by President Elias Zerhouni, M.D., a former Director of the National Institutes of Health (NIH) and Head of Global R&D at Sanofi, and CFO Adam Logal, who manages the company’s aggressive share repurchase programs and capital allocation. The board features prominent industry figures including Lead Independent Director Richard Pfenniger and ModeX CEO Gary Nabel, M.D., Ph.D., the former founding director of the NIH Vaccine Research Center, ensuring a leadership core with deep regulatory and scientific expertise.